Fifth Third Bancorp
AVTX icon

Fifth Third Bancorp’s Avalo Therapeutics AVTX Stock Holding History

Fifth Third Bancorp’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$536 Buy
+29
New +$458 ﹤0.01% 4228
2023
Q4 		– Sell
-1
Closed -$34 – 2501
2023
Q3 		$34 Buy
+1
New +$45 ﹤0.01% 2573

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fifth Third Bancorp's AVTX Position: Q2 2026 in Review

Fifth Third Bancorp opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 29 shares worth $536. The stake represents ﹤0.01% of the portfolio and ranks #4228 among its holdings. This is a return to the name: Fifth Third Bancorp previously reported a position in AVTX as recently as Q3 2023.

Fifth Third Bancorp first reported a position in AVTX in Q3 2023 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Fifth Third Bancorp held 29 shares of Avalo Therapeutics worth $536 as of Q2 2026.
  • Avalo Therapeutics was a new Fifth Third Bancorp position in Q2 2026.
  • Avalo Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #4228 holding.
  • Fifth Third Bancorp first reported a position in Avalo Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.